Category
Covering medical studies
-
Aside from Eli Lilly’s drug, what else is in the Alzheimer’s pipeline?
Eli Lilly recently announced that the FDA had granted a breakthrough therapy designation for donanemab, its investigational antibody therapy for…
-
Alzheimer’s drug approved Monday by FDA raises questions for journalists
Part two of two parts; the first ran Thursday, June 10. There’s still a great deal we don’t yet understand…
-
FDA approves new Alzheimer’s drug, but controversy persists
Part one of two parts; the second runs tomorrow, Friday, June 11. You might think that the first new drug…
-
How well do clinical studies take sex and gender differences into account?
The history of inequity in medical studies is long and harrowing, and it continues today. But at least today, there…
-
New tip sheet helps you find sources during virtual conferences
As someone who was used to covering multiple medical conferences in person each year, 2020 was a big shift. I…
-
Pfizer lays out timeline for its COVID-19 vaccine and a new flu vaccine
In a teleconference announcing the company’s first-quarter 2021 earnings earlier this month, Pfizer laid out its timeline for when different…
-
The wonderful new trend of ‘peer review’ threads on Twitter
I’ve used Twitter since 2008, but never has it been more vital to my work and news diet than throughout…
-
More resources on variants for your COVID-19 reporting toolbox
Back in January, Bara Vaida, the AHCJ core topic leader for infectious disease, wrote a helpful post on resources for…
-
Don’t forget about coverage of other vaccines
Reading the news these days, it seems the word “vaccine” automatically refers to the COVID-19 vaccine, no matter the context.…
-
Exercise caution in writing about COVID-19 breakthrough infections
There have been a number of stories in the past few weeks about people who became infected with COVID-19, even…